Hairy Cell Leukemia - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 79 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Hairy Cell Leukemia - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Hairy Cell Leukemia - Pipeline Review, H2 2014', provides an overview of the Hairy Cell Leukemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hairy Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hairy Cell Leukemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hairy Cell Leukemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Hairy Cell Leukemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Hairy Cell Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hairy Cell Leukemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hairy Cell Leukemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hairy Cell Leukemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hairy Cell Leukemia Overview 7
Therapeutics Development 8
Pipeline Products for Hairy Cell Leukemia - Overview 8
Pipeline Products for Hairy Cell Leukemia - Comparative Analysis 9
Hairy Cell Leukemia - Therapeutics under Development by Companies 10
Hairy Cell Leukemia - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Hairy Cell Leukemia - Products under Development by Companies 16
Hairy Cell Leukemia - Companies Involved in Therapeutics Development 17
Amgen Inc. 17
AstraZeneca PLC 18
GlaxoSmithKline plc 19
MedImmune, LLC 20
Plexxikon Inc. 21
Astellas Pharma Inc. 22
Incyte Corporation 23
Stemline Therapeutics, Inc. 24
Onconova Therapeutics, Inc. 25
Inbiopro Solutions Pvt. Ltd. 26
Biogenomics Limited 27
Hairy Cell Leukemia - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Target 30
Assessment by Mechanism of Action 33
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
moxetumomab pasudotox - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
(dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
SL-401 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
PLX-8394 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
rigosertib sodium - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
INCB-40093 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
AZD-6738 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
AGS-67E - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
INCB-40093 + INCB-39110 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
interferon alfa-2b - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
blinatumomab - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
IBPB-006IA - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
interferon alfa-2a - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Hairy Cell Leukemia - Recent Pipeline Updates 62
Hairy Cell Leukemia - Discontinued Products 76
Hairy Cell Leukemia - Product Development Milestones 77
Featured News & Press Releases 77
May 16, 2013: AstraZeneca's MedImmune Enrolls First Patient In Phase III Leukemia Trial Of Moxetumomab Pasudotox 77
Appendix 78
Methodology 78
Coverage 78
Secondary Research 78
Primary Research 78
Expert Panel Validation 78
Contact Us 79
Disclaimer 79

List of Tables
Number of Products under Development for Hairy Cell Leukemia, H2 2014 8
Number of Products under Development for Hairy Cell Leukemia - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Comparative Analysis by Unknown Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Hairy Cell Leukemia - Pipeline by Amgen Inc., H2 2014 17
Hairy Cell Leukemia - Pipeline by AstraZeneca PLC, H2 2014 18
Hairy Cell Leukemia - Pipeline by GlaxoSmithKline plc, H2 2014 19
Hairy Cell Leukemia - Pipeline by MedImmune, LLC, H2 2014 20
Hairy Cell Leukemia - Pipeline by Plexxikon Inc., H2 2014 21
Hairy Cell Leukemia - Pipeline by Astellas Pharma Inc., H2 2014 22
Hairy Cell Leukemia - Pipeline by Incyte Corporation, H2 2014 23
Hairy Cell Leukemia - Pipeline by Stemline Therapeutics, Inc., H2 2014 24
Hairy Cell Leukemia - Pipeline by Onconova Therapeutics, Inc., H2 2014 25
Hairy Cell Leukemia - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014 26
Hairy Cell Leukemia - Pipeline by Biogenomics Limited, H2 2014 27
Assessment by Monotherapy Products, H2 2014 28
Assessment by Combination Products, H2 2014 29
Number of Products by Stage and Target, H2 2014 32
Number of Products by Stage and Mechanism of Action, H2 2014 35
Number of Products by Stage and Route of Administration, H2 2014 37
Number of Products by Stage and Molecule Type, H2 2014 39
Hairy Cell Leukemia Therapeutics - Recent Pipeline Updates, H2 2014 62
Hairy Cell Leukemia - Discontinued Products, H2 2014 76